Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics

Ann Endocrinol (Paris). 2010 May;71(3):158-62. doi: 10.1016/j.ando.2010.02.024. Epub 2010 Apr 3.

Abstract

Congenital hypogonadotropic hypogonadisms (CHH) are a well-known cause of pubertal development failure in women. In a majority of patients, the clinical spectrum results from an insufficient and concomitant secretion of both pituitary gonadotropins LH and FSH that impedes a normal endocrine and exocrine cyclical ovary functioning after the age of pubertal activation of gonadotropic axis. In exceptional but interesting cases, they can result from an elective deficit of one of the gonadotropins follicle-stimulating hormone (FSH) or luteinizing hormone (LH) by genetic anomaly of their specific ss sub-unit. CHH prevalence, estimated from teaching hospital series, is considered to be two to five fold less important in women compared to men bearing the disease. This frequency is probably under-estimated in reason of under-diagnosis of forms with partial pubertal development. Isolated or apparently isolated forms (i.e., Kallmann syndrome with anosmia or hyposmia not spontaneously expressed by the patients) of these diseases are most of the time discovered during adolescence or in adulthood in reason of lacking, incomplete or even apparently complete pubertal development, but with almost constant primary amenorrhea. In a minority of cases and mainly in familial forms, genetic autosomal causes have been found. These cases are related to mutations of genes impinging the functioning of the pituitary-hypothalamic pathways involved in the normal secretion of LH and FSH (mutations of GnRHR, GnRH1, KISS1R/GPR54, TAC3, TACR3), which are always associated to isolated non syndromic CHH without anosmia. Some cases of mutations of FGFR1, and more rarely of its ligand FGF8, or of PROKR2 or its ligand PROK2 have been shown in women suffering from Kallmann syndrome or its hyposmic or normosmic variant. In complex syndromic causes (mutations of CHD7, leptin and leptin receptor anomalies, Prader-Willi syndrome, etc.), diagnosis of the CHH cause is most often suspected or set down before the age of puberty in reason of the associated clinical signs, but some rare cases of paucisymptomatic syndromic causes can initially be revealed during adolescence, like isolated non syndromic CHH or Kallmann syndrome.

Publication types

  • Review

MeSH terms

  • Female
  • Fibroblast Growth Factor 8 / genetics
  • Follicle Stimulating Hormone / deficiency
  • Follicle Stimulating Hormone / genetics
  • Follicle Stimulating Hormone / physiology
  • Gastrointestinal Hormones / genetics
  • Humans
  • Hypogonadism / genetics*
  • Hypogonadism / physiopathology
  • Kallmann Syndrome / genetics
  • Leptin / genetics
  • Luteinizing Hormone / deficiency
  • Luteinizing Hormone / genetics
  • Luteinizing Hormone / physiology
  • Mutation
  • Neuropeptides / genetics
  • Ovarian Follicle / cytology
  • Ovarian Follicle / physiology
  • Ovulation
  • Prader-Willi Syndrome / genetics
  • Pregnancy
  • Pregnancy Complications / genetics
  • Puberty
  • Receptor, Fibroblast Growth Factor, Type 1 / genetics
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, Leptin / genetics
  • Receptors, Peptide / genetics
  • Theca Cells / cytology
  • Theca Cells / physiology

Substances

  • FGF8 protein, human
  • Gastrointestinal Hormones
  • Leptin
  • Neuropeptides
  • PROK2 protein, human
  • PROKR2 protein, human
  • Receptors, G-Protein-Coupled
  • Receptors, Leptin
  • Receptors, Peptide
  • Fibroblast Growth Factor 8
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
  • Receptor, Fibroblast Growth Factor, Type 1